Repligen (RGEN) Competitors $160.51 -2.34 (-1.44%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RGEN vs. ALNY, BIIB, UTHR, NBIX, INCY, BMRN, EXAS, EXEL, HALO, and MDGLShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Repligen vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Halozyme Therapeutics Madrigal Pharmaceuticals Repligen (NASDAQ:RGEN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking. Which has stronger valuation & earnings, RGEN or ALNY? Repligen has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$638.76M14.08$35.60M-$0.37-433.80Alnylam Pharmaceuticals$1.83B17.37-$440.24M-$2.62-94.00 Does the MarketBeat Community favor RGEN or ALNY? Alnylam Pharmaceuticals received 729 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.49% of users gave Repligen an outperform vote. CompanyUnderperformOutperformRepligenOutperform Votes40967.49% Underperform Votes19732.51% Alnylam PharmaceuticalsOutperform Votes113876.17% Underperform Votes35623.83% Which has more volatility and risk, RGEN or ALNY? Repligen has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Do analysts recommend RGEN or ALNY? Repligen currently has a consensus target price of $185.20, suggesting a potential upside of 15.38%. Alnylam Pharmaceuticals has a consensus target price of $298.61, suggesting a potential upside of 21.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.62Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72 Is RGEN or ALNY more profitable? Repligen has a net margin of -3.36% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Repligen's return on equity of 3.90% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Repligen-3.36% 3.90% 2.72% Alnylam Pharmaceuticals -15.86%N/A -8.38% Does the media refer more to RGEN or ALNY? In the previous week, Alnylam Pharmaceuticals had 29 more articles in the media than Repligen. MarketBeat recorded 32 mentions for Alnylam Pharmaceuticals and 3 mentions for Repligen. Repligen's average media sentiment score of 0.84 beat Alnylam Pharmaceuticals' score of 0.70 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in RGEN or ALNY? 97.6% of Repligen shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAlnylam Pharmaceuticals beats Repligen on 10 of the 18 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.68B$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-433.8041.4783.3616.84Price / Sales14.08265.171,257.9179.09Price / Cash51.04192.9043.8235.97Price / Book4.563.965.324.79Net Income$35.60M-$41.02M$122.78M$224.99M7 Day Performance3.65%-1.76%-0.20%1.50%1 Month Performance8.94%0.51%3.71%4.68%1 Year Performance-7.86%-1.71%27.30%20.92% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen3.6049 of 5 stars$160.51-1.4%$185.20+15.4%-6.0%$8.68B$638.76M-433.801,783ALNYAlnylam Pharmaceuticals4.443 of 5 stars$258.17+8.5%$298.61+15.7%+30.6%$33.30B$2.09B-98.542,100Analyst RevisionNews CoverageBIIBBiogen4.7047 of 5 stars$149.38+0.4%$230.00+54.0%-42.7%$21.77B$9.61B13.498,720Short Interest ↑UTHRUnited Therapeutics4.9225 of 5 stars$364.54-0.1%$378.36+3.8%+61.5%$16.27B$2.76B16.01980Analyst UpgradeInsider TradeShort Interest ↓News CoveragePositive NewsNBIXNeurocrine Biosciences4.872 of 5 stars$142.20+0.9%$164.81+15.9%+4.5%$14.40B$2.24B38.121,200Insider TradeNews CoverageINCYIncyte4.7352 of 5 stars$72.44+2.7%$76.29+5.3%+17.0%$13.96B$4.08B517.472,524Analyst ForecastShort Interest ↓News CoverageBMRNBioMarin Pharmaceutical4.9993 of 5 stars$66.75-0.9%$94.20+41.1%-34.1%$12.72B$2.75B39.973,401Options VolumeNews CoverageEXASExact Sciences4.76 of 5 stars$57.18+1.2%$72.94+27.6%-19.2%$10.58B$2.69B-48.876,600News CoverageGap UpEXELExelixis4.5373 of 5 stars$35.21-2.2%$33.75-4.1%+60.6%$10.06B$2.08B22.571,310Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageHALOHalozyme Therapeutics4.583 of 5 stars$54.00+2.3%$60.89+12.8%+52.1%$6.87B$947.36M17.88390Short Interest ↑Analyst RevisionMDGLMadrigal Pharmaceuticals4.5458 of 5 stars$299.18-11.7%$350.83+17.3%+22.4%$6.53B$76.81M-11.9390Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RGEN) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts